Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy

AIMS: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate difference...

Descripción completa

Detalles Bibliográficos
Autores principales: Dionese, Michele, Basso, Umberto, Pierantoni, Francesco, Lai, Eleonora, Cavasin, Nicolò, Erbetta, Elisa, Jubran, Salim, Bonomi, Giorgio, Bimbatti, Davide, Maruzzo, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357407/
https://www.ncbi.nlm.nih.gov/pubmed/37485441
http://dx.doi.org/10.2144/fsoa-2023-0049
Descripción
Sumario:AIMS: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate differences in OS, response rate and toxicities, according to baseline inflammation indexes values. RESULTS: neutrophil-to-lymphocite ratio (NLR) <3 was associated to longer progression-free survival (PFS; 4.9 vs 3.1 months) and OS (15.7 vs 7.6 months); monocyte-to-lymphocite ratio (MLR) <0.4 was associated to longer PFS (4.6 vs 2.8 months). Overall response rate (ORR), disease control rate (DCR) were higher in these patients. Patients with an irAE had longer PFS and OS. CONCLUSION: baseline inflammatory indexes are prognostic for mUC patients treated with ICIs.

Ejemplares similares